Establishment of a Brain and Spinal Tumor Tissue Bank

NCT ID: NCT00686387

Last Updated: 2011-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish a Brain and Spinal Tumor Tissue/Specimen repository to serve as a resource for current and future scientific studies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glioblastoma multiforme (GBM) is the most common and lethal primary Brain and Spinal Tumor in adults. It is nearly uniformly fatal, with a median survival of approximately one year, despite modern treatment modalities. Efforts to understand why some patients live longer or shorter than the average may provide insights into the biology of these neoplasms. For years, researchers have tried to identify independent predictors that could help in treatment planning. With the recent interest in molecular biology and molecular genetics, tumor markers are now being examined as potential predictors. A marker that could predict tumor response to therapy, the likelihood of recurrence, and survival would thus be quite useful.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Multiforme Glioma Neuroectodermal Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have a suspected or confirmed diagnosis of Brain and Spinal Tumor
* Age greater than 20
* Signed consent

Exclusion Criteria

* Known HIV infection
* Any other clinical condition which, in the opinion of the principal investigator, would not allow completion of this study
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Taipei Medical University WanFang Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Taipei Medical University-Wan Fang Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kuo-Sheng Hung, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Taipei Medical University-Wan Fang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Taipei Medical University-Wan Fang Hospital

Taipei, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kuo-Sheng Hung, M.D., Ph. D.

Role: CONTACT

886-2-2930-7930 ext. 6942

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kuo-Sheng Hung, MD, PhD

Role: primary

886-2-2930-7930 ext. 6942

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008WFCRC-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.